Terms: = Chronic Myelogenous Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791 AND Prognosis
18 results:
1. siRNA-mediated downregulation of BATF3 diminished proliferation and induced apoptosis through downregulating c-Myc expression in chronic myelogenous leukemia cells.
Dabbaghipour R; Khaze Shahgoli V; Safaei S; Amini M; Tabei S; Shanehbandi D; Rahbar Farzam O; Baradaran B; Entezam M
Mol Biol Rep; 2024 Jan; 51(1):100. PubMed ID: 38217769
[TBL] [Abstract] [Full Text] [Related]
2. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Mannelli F; Guglielmelli P; Fazi P; Crea E; Piciocchi A; Vignetti M; Amadori S; Pane F; Venditti A; Vannucchi AM
Future Oncol; 2023 Jan; 19(2):103-111. PubMed ID: 36651780
[TBL] [Abstract] [Full Text] [Related]
3. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
[TBL] [Abstract] [Full Text] [Related]
4. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S
Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381
[TBL] [Abstract] [Full Text] [Related]
5. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
Scherr M; Kirchhoff H; Battmer K; Wohlan K; Lee CW; Ricke-Hoch M; Erschow S; Law E; Kloos A; Heuser M; Ganser A; Hilfiker-Kleiner D; Heidenreich O; Eder M
Leukemia; 2019 Jun; 33(6):1313-1323. PubMed ID: 30546081
[TBL] [Abstract] [Full Text] [Related]
6. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract] [Full Text] [Related]
7. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
[TBL] [Abstract] [Full Text] [Related]
8. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Lucas CM; Milani M; Butterworth M; Carmell N; Scott LJ; Clark RE; Cohen GM; Varadarajan S
Leukemia; 2016 Jun; 30(6):1273-81. PubMed ID: 26987906
[TBL] [Abstract] [Full Text] [Related]
9. Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.
Zhu X; Zhao H; Lin Z; Zhang G
Cancer Gene Ther; 2015 Dec; 22(12):573-80. PubMed ID: 26494558
[TBL] [Abstract] [Full Text] [Related]
10. Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Perekhrestenko T; Diachenko M; Sviezhentseva I; Gordienko A; Bilko D
Georgian Med News; 2015 Mar; (240):43-50. PubMed ID: 25879558
[TBL] [Abstract] [Full Text] [Related]
11. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
Zhang H; Tan S; Wang J; Chen S; Quan J; Xian J; Zhang Ss; He J; Zhang L
Exp Cell Res; 2014 Jan; 320(1):119-27. PubMed ID: 24076374
[TBL] [Abstract] [Full Text] [Related]
12. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Quintás-Cardama A; Qiu YH; Post SM; Zhang Y; Creighton CJ; Cortes J; Kornblau SM
Cancer; 2012 Nov; 118(21):5283-92. PubMed ID: 22517119
[TBL] [Abstract] [Full Text] [Related]
13. [Expression of bcl-2 gene in the evolution of chronic myelogenous leukemia to blast crisis and its implication].
Sui X; Su L; Chu J
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):27-9. PubMed ID: 11498840
[TBL] [Abstract] [Full Text] [Related]
14. [Residual disease: the hematologist's point of view].
Quesnel B; Preudhomme C
Bull Cancer; 2001 Jun; 88(6):571-5. PubMed ID: 11459703
[TBL] [Abstract] [Full Text] [Related]
15. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Ravandi F; Kantarjian HM; Talpaz M; O'Brien S; Faderl S; Giles FJ; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios MB; Albitar M
Cancer; 2001 Jun; 91(11):1964-72. PubMed ID: 11391574
[TBL] [Abstract] [Full Text] [Related]
16. De novo acute B cell leukemia/lymphoma with t(14;18).
Stamatoullas A; Buchonnet G; Lepretre S; Lenain P; Lenormand B; Duval C; Callat MP; Gaulard P; Bastard C; Tilly H
Leukemia; 2000 Nov; 14(11):1960-6. PubMed ID: 11069032
[TBL] [Abstract] [Full Text] [Related]
17. Absolute levels of MDR-1, MRP, and bcl-2 MRNA and tumor remission in acute leukemia.
Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
[TBL] [Abstract] [Full Text] [Related]
18. [Molecular diagnosis of leukemia and lymphoma].
Iida S; Ueda R
Rinsho Byori; 1994 Apr; 42(4):364-71. PubMed ID: 8176845
[TBL] [Abstract] [Full Text] [Related]
